Search results for "dipeptidyl"

showing 10 items of 54 documents

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

2020

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are so called “incretin-based therapies” (IBTs) that represent innovative therapeutic approaches and are commonly used in clinical practice for the treatment of type 2 diabetes mellitus (T2DM). The cardiovascular outcome trials (CVOTs) have provided useful information that has helped to shape changes in clinical practice guidelines for the management of T2DM. At the same time, the mechanisms that may explain the nonglycemic and cardiovascular (CV) benefits of these medications are still being explored. A summary of the main findings from CVOTs performed to-date with particular emphasis on vari…

0301 basic medicineendocrine systemmedicine.medical_specialtyDipeptidyl Peptidase 4Endocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismClass effectBody weightCardiovascular SystemIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineType 2 diabetes mellitusmedicineAnimalsHumansIntensive care medicineGlucagon-like peptide 1 receptorDipeptidyl-Peptidase IV Inhibitorsbusiness.industryDPP-4 Inhibitorsdigestive oral and skin physiologyType 2 Diabetes MellitusCardiovascular riskDPP4- inhibitorClinical Practice030104 developmental biologyCardiovascular DiseasesGlucagon-like peptide 1 receptor agonistbusinessCardiovascular outcomesMetabolism
researchProduct

Proteolytic Enzymes Clustered in Specialized Plasma-Membrane Domains Drive Endothelial Cells’ Migration

2016

In vitro cultured endothelial cells forming a continuous monolayer establish stable cell-cell contacts and acquire a "resting" phenotype; on the other hand, when growing in sparse conditions these cells acquire a migratory phenotype and invade the empty area of the culture. Culturing cells in different conditions, we compared expression and clustering of proteolytic enzymes in cells having migratory versus stationary behavior. In order to observe resting and migrating cells in the same microscopic field, a continuous cell monolayer was wounded. Increased expression of proteolytic enzymes was evident in cell membranes of migrating cells especially at sprouting sites and in shed membrane vesi…

0301 basic medicinekalininsepraseCell Membranesbeta1 integrinCelllcsh:MedicineurokinaseBiochemistryEpitheliumCell membrane0302 clinical medicineAnimal CellsMedicine and Health Sciencesdipeptidyl peptidase IVlcsh:ScienceMultidisciplinarybiologyVesicleProteolytic enzymesCell migrationProteasesEnzymesCell biologyLaboratory EquipmentCell Motilitymedicine.anatomical_structureBiochemistry030220 oncology & carcinogenesisEngineering and TechnologyBiological Culturesmatrix metalloproteinase 14Cellular Structures and OrganellesCellular TypesAnatomyResearch ArticleEquipmentCell MigrationResearch and Analysis MethodsGelatin MediaCell Linegelatinase B03 medical and health sciencescollagen type 4fibronectinmedicineHumansVesiclescollagen type 1gelatinase Alcsh:RCell MembraneBiology and Life SciencesEndothelial CellsProteinsMembrane ProteinsEpithelial CellsCell BiologyCulture MediaFibronectinBiological Tissue030104 developmental biologyMembrane proteinCell cultureProteolysisMicroscopy Electron ScanningEnzymologybiology.proteinlcsh:QCollagensDevelopmental BiologyPLOS ONE
researchProduct

The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes

2020

ABSTRACT Introduction The dipeptidyl peptidase-4 inhibitors (DPP-4is), which belong to the class of incretin-based medications, are recommended as second or third-line therapies in guidelines for the management of type 2 diabetes mellitus. They have a favorable drug tolerability and safety profile compared to other glucose-lowering agents. Objective This review discusses data concerning the use of DPP-4is and their cardiovascular profile, and gives an updated comparison with the other oral glucose-lowering medications with regards to safety and efficacy. Currently available original studies, abstracts, reviews articles, systematic reviews and meta-analyses were included in the review. Discu…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismType 2 diabetesSaxagliptinLinagliptinIncretins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumansHypoglycemic AgentsVildagliptinDipeptidyl-Peptidase IV InhibitorsPancreatitiHypoglycemic Agentbusiness.industryPancreatic NeoplasmIncretinmedicine.diseasePancreatic NeoplasmsTreatment Outcome030104 developmental biologyDiabetes Mellitus Type 2PancreatitischemistryTolerabilitySitagliptinDipeptidyl-Peptidase IV InhibitorbusinessAlogliptinHumanmedicine.drugMetabolism
researchProduct

Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nona…

2017

Abstract Aims: Nonalcoholic steatohepatitis (NASH) is characterized by steatosis, panlobular inflammation, liver fibrosis, and increased cardiovascular mortality. Dipeptidyl peptidase-4 inhibitors (gliptins) are indirect glucagon-like peptide 1 agonists with antidiabetic and anti-inflammatory activity, used for the treatment of type 2 diabetes. Their potential and underlying mechanisms to treat metabolic liver inflammation and fibrosis as well as the associated vascular dysfunction remain to be explored. Results: In the methionine/choline-deficient (MCD) diet and Mdr2−/− models of NASH and liver fibrosis, treatment with sitagliptin and linagliptin significantly decreased parameters of steat…

0301 basic medicinemedicine.medical_specialtyPhysiologyClinical BiochemistryAnti-Inflammatory AgentsGene ExpressionInflammationType 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryAntioxidantsProinflammatory cytokineMice03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicinemedicineAnimalsMyeloid CellsMolecular BiologyDipeptidyl peptidase-4General Environmental ScienceInflammationMice KnockoutDipeptidyl-Peptidase IV Inhibitorsbusiness.industryMacrophagesCell BiologyMacrophage Activationmedicine.diseaseFibrosisDietDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyLiverNADPH Oxidase 2General Earth and Planetary SciencesTumor necrosis factor alphaSteatosismedicine.symptomReactive Oxygen SpeciesbusinessBiomarkersOxidative stressAntioxidants & Redox Signaling
researchProduct

Dipeptidyl Peptidase IV as a Muscle Myokine

2020

Dipeptidyl peptidase IV (DPP-IV) is a unique serine protease that exists in a membrane bound state and in a soluble state in most tissues in the body. DPP-IV has multiple targets including cytokines, neuropeptides, and incretin hormones, and plays an important role in health and disease. Recent work suggests that skeletal muscle releases DPP-IV as a myokine and participates in control of muscle blood flow. However, few of the functions of DPP-IV as a myokine have been investigated to date and there is a poor understanding about what causes DPP-IV to be released from muscle.

0301 basic medicinemedicine.medical_specialtyanimal structuresPhysiologymuscleMini ReviewNeuropeptideIncretin030204 cardiovascular system & hematologyDipeptidyl peptidaselcsh:Physiology03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineMyokinemedicinemetalloproteasesSerine proteaseMetalloproteinasebiologyexerciselcsh:QP1-981ChemistrySkeletal musclewhey proteinpeptidasesecretome030104 developmental biologyEndocrinologymedicine.anatomical_structurebiology.proteinHormoneFrontiers in Physiology
researchProduct

Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

2021

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, inten…

AdultBlood GlucoseMalelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismType 2 diabetesIncretinsRisk AssessmentDiabetes mellitusInternal medicinemedicineElectronic Health RecordsHumansHypoglycemic AgentsMedical prescriptionSodium-Glucose Transporter 2 InhibitorsOriginal InvestigationAgedQuality Indicators Health CareRetrospective StudiesAngiologyCardiovascular risk Humans Hypoglycemic Agents Incretins Italy Male Middle Aged Retrospective Studies Risk Assessment Sodium-Glucose Transporter 2 Inhibitors Time Factors Treatment Outcome Quality Indicators Health Care Quality of care Type 2 diabetes Adult Aged Aged 80 and over Biomarkers Blood Glucose Cardiovascular Diseases Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Heart Disease Risk Factors Female Electronic Health RecordsAged 80 and overDipeptidyl-Peptidase IV Inhibitorsbusiness.industryMedical recordQuality of careType 2 diabetesRetrospective cohort studyMiddle AgedCardiovascular riskmedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2ItalyCardiovascular DiseasesHeart Disease Risk Factorslcsh:RC666-701AlbuminuriaFemaleObservational studymedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular Diabetology
researchProduct

Enzymatic Activity of CD26 (Dipeptidylpeptidase IV) is not Required for Its Signalling Function in T Cells

1993

Abstract CD26 is a proteolytic enzyme (dipeptidylpeptidase IV) expressed on the T cell surface that defines an alternative activation signal for human T lymphocytes. Crosslinking of CD26 via monoclonal antibodies triggers proliferation and cytotoxicity in preactivated T cells. In this study, we used highly specific competitive and irreversible inhibitors of dipeptidylpeptidase IV to study the role of the enzymatic activity in activation of CD26- transfected T cells as well as of CD26-expressing normal human T cell clones. These inhibitors at concentrations that blocked up to 95% of the enzymatic activity, did not specifically inhibit T cell activation neither via TCR/CD3 nor via CD26 itself…

Antigens Differentiation T-LymphocyteDipeptidyl Peptidase 4T-LymphocytesT cellCD3ImmunologyBiologyLymphocyte ActivationCell LineMiceTumor Cells CulturedmedicineAnimalsHumansImmunology and AllergyCytotoxic T cellDipeptidyl-Peptidases and Tripeptidyl-PeptidasesT-cell receptorProteolytic enzymesHematologyTransfectionT lymphocyteCytotoxicity Tests ImmunologicCell biologymedicine.anatomical_structureBiochemistrybiology.proteinInterleukin-2Clone (B-cell biology)Signal TransductionImmunobiology
researchProduct

Function of Dipeptidyl Peptidase IV (CD26, Tp103) in Transfected Human T Cells

1993

CD26 (Tp103) is a proteolytic enzyme (dipeptidyl peptidase IV) expressed on the T cell surface that defines an alternative activation signal for human T lymphocytes. It is absent from or present in only low amounts on resting T cells but it is expressed strongly after activation. Crosslinking of CD26/Tp103 via the monoclonal antibody CB.1 triggers functional activities in preactivated T cells. To study the molecular requirements for T cell activation via CD26 we transfected a cDNA encoding CD26 into several CD26-negative cells. In Jurkat T cell leukemia cells that normally do not express the CD26 antigen, the transfected CD26 molecule is functional because the monoclonal antibody CB.1 induc…

Antigens Differentiation T-LymphocyteDipeptidyl Peptidase 4T-LymphocytesT cellZAP70ImmunologyT-cell receptorReceptors Antigen T-CellBiologyTransfectionNatural killer T cellMolecular biologyJurkat cellsRecombinant ProteinsCell LineMicemedicine.anatomical_structureAntigenTumor Cells CulturedmedicineAnimalsHumansCytotoxic T cellIL-2 receptorDipeptidyl-Peptidases and Tripeptidyl-PeptidasesCellular Immunology
researchProduct

Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease.

2015

Cardiovascular disease is a leading cause of death and reduced quality of life worldwide. Arterial vessels are a primary target for endothelial dysfunction and atherosclerosis, which is accompanied or even driven by increased oxidative stress. Recent research in this field identified different sources of reactive oxygen and nitrogen species contributing to the pathogenesis of endothelial dysfunction. According to lessons from the past, improvement of endothelial function and prevention of cardiovascular disease by systemic, unspecific, oral antioxidant therapy are obviously too simplistic an approach. Source- and cell organelle-specific antioxidants as well as activators of intrinsic antiox…

Antioxidantmedicine.medical_treatmentGlucagon-Like PeptidesInflammationDiseaseReviewBiologymedicine.disease_causeCatalysisAntioxidantsendothelial dysfunctionInorganic ChemistryPathogenesislcsh:Chemistrycardiovascular diseasemedicineAnimalsHumansImmunologic FactorsPhysical and Theoretical ChemistryEndothelial dysfunctionMolecular Biologylcsh:QH301-705.5Spectroscopyglucagon-like peptide analogsCause of deathInflammationOrganic ChemistryGeneral Medicinemedicine.diseaseComputer Science ApplicationsClinical trialOxidative Stresslcsh:Biology (General)lcsh:QD1-999Cardiovascular DiseasesImmunologyEndothelium Vascularmedicine.symptomdipeptidyl peptidase-4 inhibitorsOxidative stressInternational journal of molecular sciences
researchProduct

EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?

2022

Type 2 diabetes mellitus (T2DM) is a serious public health concern as it is one of the most common chronic diseases worldwide due to social and economic developments that have led to unhealthy lifestyles, with a considerable impact both in terms of morbidity and mortality. The management of T2DM, before starting specific therapies, includes cornerstones such as healthy eating, regular exercise and weight loss. Strict adherence to the Mediterranean diet (MedDiet) has been related to an inverse association with the risk of T2DM onset, as well as an improvement in glycaemic control; in particular, thanks to the consumption of extra virgin olive oil (EVOO). Agonists of gut-derived glucagon-like…

Blood GlucoseDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agent[SDV]Life Sciences [q-bio]Organic ChemistryEVOOT2DMGeneral MedicineIncretinIncretinsCatalysisComputer Science ApplicationsInorganic ChemistryDiabetes Mellitus Type 2Glucagon-Like Peptide 1Insulin SecretionHumansHypoglycemic AgentsMedDietPhysical and Theoretical ChemistryGLP-1Molecular BiologySpectroscopyHuman
researchProduct